{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T10:07:16Z","timestamp":1725012436165},"reference-count":62,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T00:00:00Z","timestamp":1535932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Migraine is a severe, disabling condition, ranked by World Health Organization as the sixth highest cause of disability worldwide. It greatly affects patients\u2019 quality of life, functionality, and physical and mental health. The financial burden of migraine on the UK economy is conservatively estimated at \u00a33.42 billion per year.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>The authors sought to perform an evidence-based literature review of the safety and efficacy of botulinum toxin type A (onaBoNTA) in the prophylactic treatment of adult patients suffering with chronic migraine (CM) compared to placebo. After the best evidence is identified, it will be utilized to formulate a protocol for doctors managing CM in their aesthetic clinic.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A comprehensive search of the current literature on the topic was performed by H.M. using Pubmed MEDLINE electronic database on March 1, 2018. All articles up to and inclusive of this date were included. Articles were limited to human studies and those in the English language. In vitro and animal studies were excluded.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 260 articles were identified. Of these, the excellent-quality, high-strength (level 1A) trials were short-listed to answer the research question.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>There is high-quality, level 1A evidence to support onaBoNTA treatment in adults with CM is well tolerated and considered safe. However, it is associated with increased risk of adverse events and still some uncertainty exists associated with the degree onaBoNTA improves outcome measures compared to placebo. These data have been used to formulate The London Aesthetic Migraine Protocol (LAMP) to provide safe, evidence-based guidance for appropriately trained and experienced aesthetic practitioners to manage CM in their aesthetic clinics.<\/jats:p><\/jats:sec><jats:sec><jats:title>Level of Evidence: 1<\/jats:title><jats:p\/><\/jats:sec>","DOI":"10.1093\/asj\/sjy224","type":"journal-article","created":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T07:01:15Z","timestamp":1535958075000},"page":"898-907","source":"Crossref","is-referenced-by-count":4,"title":["A Critical Review of Botulinum Toxin Type A in the Prophylactic Treatment of Chronic Migraine in Adults"],"prefix":"10.1093","volume":"39","author":[{"given":"Hanieh","family":"Mimeh","sequence":"first","affiliation":[{"name":"Royal Society of Medicine, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Maria","family":"Fenech Magrin","sequence":"additional","affiliation":[{"name":"Queen Mary University of London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Myers","sequence":"additional","affiliation":[{"name":"Reconstructive, and Aesthetic Surgery, Blizard Institute, Barts and the London School of Medicine and Dentistry, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali M","family":"Ghanem","sequence":"additional","affiliation":[{"name":"Reconstructive, and Aesthetic Surgery, Blizard Institute, Barts and the London School of Medicine and Dentistry, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,9,3]]},"reference":[{"issue":"7","key":"2023011002161696700_CIT0001","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3111\/13696998.2013.802694","article-title":"The cost-effectiveness of onabotulinumtoxinA for the prophylaxis of headache in adults with chronic migraine in the UK","volume":"16","author":"Batty","year":"2013","journal-title":"J Med Econ"},{"key":"2023011002161696700_CIT0002"},{"issue":"12","key":"2023011002161696700_CIT0003","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1177\/1756285617731521","article-title":"OnabotulinumtoxinA in the treatment of patients with chronic migraine: clinical evidence and experience","volume":"10","author":"Chiang","year":"2017","journal-title":"Ther Adv Neurol Disord"},{"key":"2023011002161696700_CIT0004","first-page":"1003","article-title":"OnabotulinumtoxinA for chronic migraine: a critical appraisal","volume":"11","author":"Gooriah","year":"2015","journal-title":"Ther Clin Risk Manag"},{"issue":"3","key":"2023011002161696700_CIT0005","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1177\/0333102410381145","article-title":"Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS)","volume":"31","author":"Blumenfeld","year":"2011","journal-title":"Cephalalgia"},{"issue":"9","key":"2023011002161696700_CIT0006","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1177\/0333102413485658","article-title":"The international classification of headache disorders, 3rd edition (beta version)","volume":"33","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2013","journal-title":"Cephalalgia"},{"issue":"7","key":"2023011002161696700_CIT0007","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.3390\/toxins7072659","article-title":"Treatment of chronic migraine with OnabotulinumtoxinA: mode of action, efficacy and safety","volume":"7","author":"Szok","year":"2015","journal-title":"Toxins (Basel)"},{"issue":"7","key":"2023011002161696700_CIT0008","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.3390\/toxins7072615","article-title":"Treatment of chronic migraine with focus on botulinum neurotoxins","volume":"7","author":"Schaefer","year":"2015","journal-title":"Toxins (Basel)"},{"key":"2023011002161696700_CIT0009","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/nyas.12488","article-title":"Development of onabotulinumtoxinA for chronic migraine","volume":"1329","author":"Whitcup","year":"2014","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"2023011002161696700_CIT0010","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3988\/jcn.2012.8.2.89","article-title":"Sensitization of the trigeminovascular pathway: perspective and implications to migraine pathophysiology","volume":"8","author":"Bernstein","year":"2012","journal-title":"J Clin Neurol"},{"issue":"6","key":"2023011002161696700_CIT0011","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2165\/00023210-200418060-00001","article-title":"Central sensitisation and cutaneous allodynia in migraine: implications for treatment","volume":"18","author":"Landy","year":"2004","journal-title":"CNS Drugs"},{"issue":"16","key":"2023011002161696700_CIT0012","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1001\/jama.2012.505","article-title":"Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults: a meta-analysis","volume":"307","author":"Jackson","year":"2012","journal-title":"JAMA"},{"key":"2023011002161696700_CIT0013","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2147\/NDT.S17923","article-title":"Critical analysis of the use of onabotulinumtoxinA (botulinum toxin type A) in migraine","volume":"8","author":"Robertson","year":"2012","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2023011002161696700_CIT0014","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.parkreldis.2011.06.013","article-title":"Updates on the antinociceptive mechanism hypothesis of botulinum toxin A","volume":"17","author":"Aoki","year":"2011","journal-title":"Parkinsonism Relat Disord"},{"issue":"7","key":"2023011002161696700_CIT0015","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.3390\/toxins7072435","article-title":"Botulinum toxin as a pain killer: plays and actions in antinociception","volume":"7","author":"Dong-Wan","year":"2015","journal-title":"Toxins"},{"key":"2023011002161696700_CIT0016","article-title":"Botulinum toxin A for chronic migraines: clinical effectiveness","author":"Pejic","year":"2018","journal-title":"Ontario, Canada: CADTH"},{"key":"2023011002161696700_CIT0017","article-title":"Comparative Effectiveness Review No. 103. Minnesota Evidence-based Practice Center","volume-title":"Migraine in Adults: Preventive Pharmacologic Treatments","author":"Shamliyan","year":"2013"},{"key":"2023011002161696700_CIT0018","volume-title":"Botulinum Toxin Type A for Prophylactic Treatment of Chronic Migraine","author":"Kim","year":"2014"},{"key":"2023011002161696700_CIT0019","article-title":"CADTH Canadian Drug Expert Committee (CDEC) clinical review report: OnabotulinumtoxinA for Injection (Botox): for the Prophylaxis of Headaches in Adults with Chronic Migraine","journal-title":"CADTH Common Drug Reviews"},{"issue":"6","key":"2023011002161696700_CIT0020","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1067\/mhn.2000.110960","article-title":"Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study","volume":"123","author":"Binder","year":"2000","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"2","key":"2023011002161696700_CIT0021","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1526-4610.2007.00963.x","article-title":"Botulinum Toxin Type A in the treatment of chronic migraine without medication overuse","volume":"48","author":"Freitag","year":"2008","journal-title":"Headache"},{"issue":"5 Suppl","key":"2023011002161696700_CIT0022","first-page":"B113","article-title":"Botulinum toxin type-a in the prevention of migraine: a double-blind controlled trial","volume":"78","author":"Vo","year":"2007","journal-title":"Aviat Space Environ Med"},{"issue":"7","key":"2023011002161696700_CIT0023","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1177\/0333102410364676","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial","volume":"30","author":"Aurora","year":"2010","journal-title":"Cephalalgia"},{"issue":"7","key":"2023011002161696700_CIT0024","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1177\/0333102410364677","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial","volume":"30","author":"Diener","year":"2010","journal-title":"Cephalalgia"},{"issue":"9","key":"2023011002161696700_CIT0025","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1111\/j.1526-4610.2011.01990.x","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program","volume":"51","author":"Aurora","year":"2011","journal-title":"Headache"},{"issue":"1-2","key":"2023011002161696700_CIT0026","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jns.2013.05.003","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline","volume":"331","author":"Silberstein","year":"2013","journal-title":"J Neurol Sci"},{"key":"2023011002161696700_CIT0027","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1177\/0333102411417901","article-title":"Guidelines for controlled trials of drugs in migraine: third edition. A guide for investigators","volume":"32","author":"Tfelt-Hansen","year":"2012","journal-title":"Cephalagia"},{"issue":"15","key":"2023011002161696700_CIT0028","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1212\/WNL.0b013e318232ab65","article-title":"OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine","volume":"77","author":"Lipton","year":"2011","journal-title":"Neurology"},{"issue":"9","key":"2023011002161696700_CIT0029","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1177\/0333102416652092","article-title":"OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment: Pooled results from the PREEMPT randomized clinical trial program","volume":"36","author":"Lipton","year":"2016","journal-title":"Cephalalgia"},{"key":"2023011002161696700_CIT0030","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1129-2377-15-54","article-title":"Prospective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, U.K","volume":"15","author":"Khalil","year":"2014","journal-title":"J Headache Pain"},{"key":"2023011002161696700_CIT0031","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1186\/s40064-015-1636-9","article-title":"OnabotulinumtoxinA 155 U in medication overuse headache: a two years prospective study","volume":"4","author":"Negro","year":"2015","journal-title":"Springerplus"},{"issue":"8","key":"2023011002161696700_CIT0032","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1111\/j.1526-4610.2012.02164.x","article-title":"Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine","volume":"52","author":"Winner","year":"2012","journal-title":"Headache"},{"issue":"1","key":"2023011002161696700_CIT0033","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/ane.12171","article-title":"OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program","volume":"129","author":"Aurora","year":"2014","journal-title":"Acta Neurol Scand"},{"issue":"9","key":"2023011002161696700_CIT0034","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1136\/jnnp-2013-307149","article-title":"Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT","volume":"86","author":"Silberstein","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"2023011002161696700_CIT0035","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s10194-016-0676-z","article-title":"Onabotulinumtoxin-A treatment in Greek patients with chronic migraine","volume":"17","author":"Vikelis","year":"2016","journal-title":"J Headache Pain"},{"key":"2023011002161696700_CIT0036","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10072-014-1739-z","article-title":"Botulinum toxin A: a new option for treatment of chronic migraine with medication overuse","volume":"35","author":"Grazzi","year":"2014","journal-title":"Neurol Sci"},{"issue":"2","key":"2023011002161696700_CIT0037","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s10194-011-0294-8","article-title":"Experience with onabotulinumtoxinA (BOTOX) in chronic refractory migraine: focus on severe attacks","volume":"12","author":"Oterino","year":"2011","journal-title":"J Headache Pain"},{"issue":"1","key":"2023011002161696700_CIT0038","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s10194-017-0802-6","article-title":"Real-life use of onabotulinumtoxinA for symptom relief in patients with chronic migraine: REPOSE study methodology and baseline data","volume":"18","author":"Davies","year":"2017","journal-title":"J Headache Pain"},{"issue":"14","key":"2023011002161696700_CIT0039","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1177\/0333102417724150","article-title":"Utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine from an observational study in Europe","volume":"37","author":"Matharu","year":"2017","journal-title":"Cephalalgia"},{"issue":"2","key":"2023011002161696700_CIT0040","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1177\/1756285616677005","article-title":"Botulinum toxin in the management of chronic migraine: clinical evidence and experience","volume":"10","author":"Escher","year":"2017","journal-title":"Ther Adv Neurol Disord"},{"issue":"1","key":"2023011002161696700_CIT0041","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s10194-018-0840-8","article-title":"Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study","volume":"19","author":"Blumenfeld","year":"2018","journal-title":"J Headache Pain"},{"issue":"4","key":"2023011002161696700_CIT0042","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s10194-011-0339-z","article-title":"Botulinum toxin type-A in the prophylactic treatment of medication-overuse headache: a multicenter, double-blind, randomized, placebo-controlled, parallel group study","volume":"12","author":"Sandrini","year":"2011","journal-title":"J Headache Pain"},{"key":"2023011002161696700_CIT0043","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jns.2016.01.054","article-title":"Factors associated with favorable outcome in botulinum toxin A treatment for chronic migraine: a clinic-based prospective study","volume":"363","author":"Lee","year":"2016","journal-title":"J Neurol Sci"},{"issue":"2","key":"2023011002161696700_CIT0044","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1526-4610.2007.00914.x","article-title":"Predictors of response to botulinum toxin type A (BoNTA) in chronic daily headache","volume":"48","author":"Mathew","year":"2008","journal-title":"Headache"},{"issue":"1","key":"2023011002161696700_CIT0045","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1055\/s-0036-1571443","article-title":"The use of botulinum toxin in the management of headache disorders","volume":"36","author":"Silberstein","year":"2016","journal-title":"Semin Neurol"},{"key":"2023011002161696700_CIT0046","doi-asserted-by":"crossref","first-page":"655","DOI":"10.3389\/fneur.2017.00655","article-title":"Stopping onabotulinum treatment after the first two cycles might not be justified: results of a real-life monocentric prospective study in chronic migraine","volume":"8","author":"Sarchielli","year":"2017","journal-title":"Front Neurol"},{"key":"2023011002161696700_CIT0047","doi-asserted-by":"crossref","unstructured":"Matharu M , PascualJ, Nilsson RemahlI, et al Real-world utilization and safety of OnabotulinumtoxinA for chronic migraine from an observational study in the European Union. Paper presented at: European Headache and Migraine Trust (EHMTIC); September 15-18, 2016; Glasgow, UK.","DOI":"10.1016\/j.toxicon.2016.11.172"},{"issue":"2","key":"2023011002161696700_CIT0048","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/ene.13523","article-title":"OnabotulinumtoxinA in chronic migraine: predictors of response. A prospective multicentre descriptive study","volume":"25","author":"Dom\u00ednguez","year":"2018","journal-title":"Eur J Neurol"},{"issue":"9","key":"2023011002161696700_CIT0049","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.4065\/80.9.1126","article-title":"Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial","volume":"80","author":"Silberstein","year":"2005","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"2023011002161696700_CIT0050","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/ene.12393","article-title":"Pooled analysis of the safety and tolerability of OnabotulinumtoxinA in the treatment of chronic migraine","volume":"21","author":"Diener","year":"2014","journal-title":"Eur J Neurol"},{"issue":"6","key":"2023011002161696700_CIT0051","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/j.1526-4610.2010.01678.x","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program","volume":"50","author":"Dodick","year":"2010","journal-title":"Headache"},{"issue":"13","key":"2023011002161696700_CIT0052","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1002\/mds.23254","article-title":"Meta-analysis of neutralizing antibody conversion with OnabotulinumtoxinA (BOTOX\u00ae) across multiple indications","volume":"25","author":"Naumann","year":"2010","journal-title":"Mov Disord"},{"issue":"4","key":"2023011002161696700_CIT0053","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1159\/000228987","article-title":"Botulinum toxin as preventive treatment for migraine: a randomized double-blind study","volume":"62","author":"Petri","year":"2009","journal-title":"Eur Neurol"},{"issue":"1","key":"2023011002161696700_CIT0054","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1526-4610.2010.01807.x","article-title":"Prophylactic botulinum type A toxin complex (Dysport\u00ae) for migraine without aura","volume":"51","author":"Chankrachang","year":"2011","journal-title":"Headache"},{"key":"2023011002161696700_CIT0055","first-page":"192","article-title":"IncobotulinumtoxinA (Xeomin\u00ae) and OnabotulinumtoxinA (Botox\u00ae) for chronic migraine headache: experience with higher doses and changes to the injection technique","volume":"2","author":"Salazar","year":"2014","journal-title":"J Neurol Disord"},{"issue":"8","key":"2023011002161696700_CIT0056","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.clinthera.2015.05.509","article-title":"IncobotulinumtoxinA for migraine: a retrospective case series","volume":"37","author":"Kazerooni","year":"2015","journal-title":"Clin Ther"},{"issue":"10","key":"2023011002161696700_CIT0057","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1111\/j.1526-4610.2009.01566.x","article-title":"A double-blind comparison of OnabotulinumtoxinA (BOTOX) and topiramate (TOPAMAX) for the prophylactic treatment of chronic migraine: a pilot study","volume":"49","author":"Mathew","year":"2009","journal-title":"Headache"},{"issue":"1","key":"2023011002161696700_CIT0058","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1526-4610.2010.01796.x","article-title":"A multi-center double-blind pilot comparison of OnabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine","volume":"51","author":"Cady","year":"2011","journal-title":"Headache"},{"issue":"6","key":"2023011002161696700_CIT0059","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.clineuro.2010.02.004","article-title":"Botulinum toxin type A versus amitriptyline for the treatment of chronic daily migraine","volume":"112","author":"Magalh\u00e3es","year":"2010","journal-title":"Clin Neurol Neurosurg"},{"issue":"9","key":"2023011002161696700_CIT0060","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1111\/j.1526-4610.2010.01766.x","article-title":"Method of injection of OnabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program","volume":"50","author":"Blumenfeld","year":"2010","journal-title":"Headache"},{"issue":"19","key":"2023011002161696700_CIT0061","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1212\/WNL.0000000000002560","article-title":"Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: report of the Guideline Development Subcommittee of the American Academy of Neurology","volume":"86","author":"Simpson","year":"2016","journal-title":"Neurology"},{"key":"2023011002161696700_CIT0062"}],"container-title":["Aesthetic Surgery Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/asj\/article-pdf\/39\/8\/898\/48585161\/asj_39_8_898.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/asj\/article-pdf\/39\/8\/898\/48585161\/asj_39_8_898.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T21:29:37Z","timestamp":1720560577000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/asj\/article\/39\/8\/898\/5089919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,3]]},"references-count":62,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,9,3]]},"published-print":{"date-parts":[[2019,7,12]]}},"URL":"https:\/\/doi.org\/10.1093\/asj\/sjy224","relation":{},"ISSN":["1090-820X","1527-330X"],"issn-type":[{"value":"1090-820X","type":"print"},{"value":"1527-330X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,8]]},"published":{"date-parts":[[2018,9,3]]}}}